Gold Sector: Gold softens but strong margins remain
About the author:
- Author name:
- By Mat Collings
- Job title:
- Research Analyst
- Date posted:
- 30 November 2020, 2:30 PM
- Sectors Covered:
- We refresh our three gold names valued on a flat forward gold price, using US$1,750/oz and 0.74 AUD/USD (from US$1,900 and 0.725).
- The gold price has softened on the back of increasing global confidence as Covid-19 vaccine developments make progress.
- The path to normal remains rocky and we think markets are too upbeat on vaccine timing – we expect volatility will create trading opportunities.
- While improving global sentiment may push gold prices lower, central bank stimulus measures (i.e. money printing) need to be watched as a counter-balance.
- Stocks appear oversold compared to our revised price targets. We retain an ADD rating for Ramelius Resources Limited (ASX:RMS), Red 5 Limited (ASX:RED) and Regis Resources Limited (ASX:RRL), although weakness may persist in the short term, with RMS our preferred stock from the group.
Margins reduced but still high
Despite the softening gold price, and relative strengthening of the AUD, the AUD gold price remains around A$2,450/oz at the time of writing, and we update our modelling to A$2,364/oz.
At this price, most gold companies are still earning close to A$1,000/oz of gold produced compared to their all in sustaining costs.
We see the current falls in gold stocks as driven by investor sentiment rather than a change to the underlying fundamentals of the gold producers and their profitability.
Uncertainty still looks like the only certainty
There are likely still tough months ahead for the global economy. Northern hemisphere winter is approaching and though vaccine trials are promising the market appears too upbeat on the timelines for approval and deployment.
Recent market moves appear to be glossing over the difficulties still ahead, with signs of a full bull market as fund manager cash levels hit new lows.
Volatility will create trading opportunities as sentiment shifts.
Our valuation methodology
We have moved our base case gold price to US$1,750/oz and our AUD:USD exchange rate to 0.74.
We value the junior and mid-tier gold miners using a flat forward gold price, reflecting our view that these stocks respond quickly to moves in the spot gold price and sentiment rather than to long term price forecasts.
Sensitivity tables are included for gold price and exchange rates to provide an insight on the potential upside and downside.
We retain Add ratings across the gold stocks and our target price moves to $2.44 from $2.86 for RMS, to $0.41 from $0.52 for RED, and to $4.57 from $5.74 for RRL.
We expect the shift away from gold stocks to persist in the near term with investors looking for a rebound in Covid-19 impacted stocks as vaccine researchers continue to report positive progress.
As gold companies report Q2 production and earnings in January, we think the strength of cash flows will remind the market of the margins producers are still making despite the switch in sentiment.
Add to that some volatility during what is unlikely to be a straight line path to normality over the next 12 months and we believe gold stocks have been oversold, with good potential for trading opportunities over the coming months in the gold producers as the markets swing between a risk on / risk off view.
Find out more
Morgans clients can access further analysis by browsing the latest research on our client website. If you would like access or more information, please contact your adviser or nearest Morgans office.
Need access to our research?
You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team.
Create trial account
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.